We Are RenoVate Therapeutics
PIONEERING A GROUNDBREAKING, CELL-FREE, BIOLOGICAL DRUG FOR CHRONIC KIDNEY DISEASE
More than 850 million people worldwide are affected by CKD, almost 10% of the global population, impacting individuals across all ages and races. Despite the high prevalence, current treatments fail to stop disease progression, leaving many patients facing dialysis or transplantation.
THIS IS WHERE WE AIM TO MAKE A SIGNIFICANT CHANGE.
Our revolutionary technology harnesses the natural mechanisms of the kidney as a therapeutic approach. We use a patented method to culture and expand kidney cells derived from urine, growing them in a unique 3D system that mimics healthy kidney function. These cells secrete regenerative, anti-fibrotic substances which we use as a therapy, making it the first-ever secretome-based drug for CKD. Designed to treat all CKD patients, regardless of the cause, our treatment aims to halt fibrosis and prevent progression to end-stage renal failure.
Currently, we are advancing preclinical trials, optimizing dosing and delivery, and scaling manufacturing to bring our therapy to patients worldwide. Backed by Sheba Medical Center and well-known global partners, we are committed to transforming the future of CKD treatment.
JOIN US IN REVOLUTIONIZING KIDNEY CARE.
